Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

TScan Therapeutics Q1 EPS $(0.26) Beats $(0.29) Estimate, Sales $2.17M Beat $1.10M Estimate

Author: Benzinga Newsdesk | May 06, 2025 07:03am
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.29) by 10.34 percent. This is a 18.75 percent increase over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $2.17 million which beat the analyst consensus estimate of $1.10 million by 96.47 percent. This is a 283.57 percent increase over sales of $566.00 thousand the same period last year.

Posted In: TCRX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist